Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 7:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 621 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: SUBLOCADE Clear all
Completed Phase 1 Interventional

ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine

NCT01366001
View directory record Official record
Conditions
Cocaine Abuse
Interventions
ALKS 33-BUP, ALKS 33, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
21 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2012 · Synced Oct 30, 2026, 7:16 PM EDT
Completed Phase 2 Interventional

Comparison of Buprenorphine to Morphine in Treatment of Neonatal Abstinence Syndrome (NAS)

NCT01708707
View directory record Official record
Conditions
Neonatal Abstinence Syndrome, Neonatal Withdrawal Syndrome
Interventions
Buprenorphine, Morphine Sulfate
Drug
Lead sponsor
Pediatrix
Other
Eligibility
Up to 1 Year
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 30, 2026, 7:16 PM EDT
Completed Phase 2 Interventional

Buprenorphine Pharmacology Related to Addiction Treatment - 18

NCT00000236
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 17, 2005 · Synced Oct 30, 2026, 7:16 PM EDT
Completed Phase 1Phase 2 Interventional

ALK33BUP-201: Safety and Tolerability Study of ALKS 33-BUP (ALKS 5461) Administration in Subjects With MDD

NCT01381107
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ALKS 5461, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
St. Petersburg, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 23, 2011 · Synced Oct 30, 2026, 7:16 PM EDT
Recruiting Phase 2Phase 3 Interventional

Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder

NCT05011266
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Buprenorphine/naloxone, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Rockville, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 30, 2026, 7:16 PM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings

NCT06854029
View directory record Official record
Conditions
HIV Infections, Opioid Use Disorder, Incarceration; Lens
Interventions
Cabotegravir Injection, Cabotegravir Pill, Buprenorphine injection, Buprenorphine Pill
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 30, 2026, 7:16 PM EDT
Completed Not applicable Interventional

tAN for PTSD and OUD in Buprenorphine Therapy

NCT06130501
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Opioid Use Disorder
Interventions
Sparrow Ascent tAN, Sparrow Ascent Active Sham
Device
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cape Girardeau, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 30, 2026, 7:16 PM EDT
Completed Not applicable Interventional

SMART Trial for Buprenorphine-Naloxone Medication Assisted Treatment Adherence

NCT04080180
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Contingency Management, Brief Motivational Interviewing + Substance Free Activities + Mindfulness
Behavioral
Lead sponsor
Karen Derefinko, PhD
Other
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 30, 2026, 7:16 PM EDT
Withdrawn Phase 4 Interventional

Buprenorphine/Naloxone Micro-Dosing for Postoperative Pain Management in Opioid-Tolerant Patients

NCT04771689
View directory record Official record
Conditions
Post-operative Pain
Interventions
Buprenorphine/Naloxone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 30, 2026, 7:16 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effects of Water Temperature on the Cold Pressor Test

NCT03083626
View directory record Official record
Conditions
Chronic Pain
Interventions
Cold pressor test
Other
Lead sponsor
Georgetown University
Other
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 30, 2026, 7:16 PM EDT
Completed Phase 3 Interventional Results available

Medication Treatment for Opioid Use Disorder in Expectant Mothers

NCT03918850
View directory record Official record
Conditions
Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome, Drug Abuse in Pregnancy
Interventions
Buprenorphine Injection, Buprenorphine Sublingual Product
Drug
Lead sponsor
T. John Winhusen, PhD
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
12
States / cities
Jacksonville, Florida • Boston, Massachusetts • Albuquerque, New Mexico + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 30, 2026, 7:16 PM EDT
Completed Phase 4 Interventional Results available

Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence

NCT00555425
View directory record Official record
Conditions
Opiate Dependence
Interventions
Behavioral: Buprenorphine/naloxone maintenance (Mtn), Behavioral: Buprenorphine/naloxone detoxification (Dtx)
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Oct 30, 2026, 7:16 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Multimodal Fetal and Placental Imaging and Biomarkers of Clinical Outcomes in Opioid Use Disorder

NCT06415994
View directory record Official record
Conditions
Opioid Use Disorder, Substance-Related Disorders, Pregnancy Related, Narcotic-Related Disorders, Buprenorphine Dependence, Methadone Dependence
Interventions
Buprenorphine or Methadone Treatment, Fetal and Placental MRI, Child Developmental Assessment, Questionnaires, Blood and Placental Samples
Drug · Diagnostic Test · Behavioral + 1 more
Lead sponsor
Senthil Sadhasivam
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
2
States / cities
Indianapolis, Indiana • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 30, 2026, 7:16 PM EDT
Completed Not applicable Interventional

Rural Expanded Access to OUD Care & Linkage Using Toxicologists for Telehealth Initiated Treatment

NCT05711056
View directory record Official record
Conditions
Opioid Use, Opioid Abuse
Interventions
Sociobehavioral Intervention
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 7:16 PM EDT
Completed Phase 3 Interventional Results available

Buprenorphine for Treatment Resistant Depression

NCT01407575
View directory record Official record
Conditions
Depression, Depressive Disorder, Depressive Disorder, Major
Interventions
Buprenorphine, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 30, 2026, 7:16 PM EDT
Recruiting Not applicable Interventional

Telehealth vs In-Person Evaluation of Addiction Treatment After Visiting the Emergency Department

NCT06961058
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
referral to telehealth treatment, referral to in person treatment
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
El Centro, California • Sacramento, California • Sylmar, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 30, 2026, 7:16 PM EDT
Completed Not applicable Interventional Results available

Intensive Outpatient Versus Outpatient Treatment With Buprenorphine Among African Americans

NCT01096550
View directory record Official record
Conditions
Drug Dependence
Interventions
Outpatient, Intensive Outpatient
Behavioral
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years to 85 Years
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Oct 30, 2026, 7:16 PM EDT
Recruiting Phase 4 Interventional

A Bundled Intervention to End Opioid Overdoses

NCT07485335
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Overdose
Interventions
Bundled intervention (Experimental), control group, Buprenorphine (Experimental), Scheduled Peer Support Specialist (Experimental), Telemedicine Buprenorphine Treatment
Other · Drug · Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 30, 2026, 7:16 PM EDT
Completed Not applicable Interventional Results available

Emergency Department Longitudinal Integrated Care

NCT03699085
View directory record Official record
Conditions
Opioid-use Disorder, Emergency Department
Interventions
ED-LINC
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 30, 2026, 7:16 PM EDT
Withdrawn Phase 3 Interventional

The Safety of Using Buprenorphine With Naloxone in a Buccal Film to Initiate Treatment of Opioid Dependent Subjects

NCT02516436
View directory record Official record
Conditions
Opioid Dependence
Interventions
BEMA Buprenorphine NX, Buprenorphine
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2017
U.S. locations
3
States / cities
Birmingham, Alabama • Orem, Utah • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 30, 2026, 7:16 PM EDT
Completed Not applicable Interventional

Blockade Efficacy of Buprenorphine/Naloxone For Opioid Dependence

NCT00134888
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 30, 2026, 7:16 PM EDT
Completed Phase 2 Interventional

Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)

NCT05262270
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Extended-Release Naltrexone, Extended Release Buprenorphine, Placebo (PLB) Injectable matched to XR-NTX, Placebo (PLB) Injectable matched to XR-BUP
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 30, 2026, 7:16 PM EDT
Terminated Phase 3 Interventional Results available

Safety of Buprenorphine Transdermal Patch (BTDS) in Osteoarthritis Pain: a 52-Week Extension Phase

NCT01135524
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal patch
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
89
States / cities
Alabaster, Alabama • Birmingham, Alabama • Fairfield, Alabama + 75 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 30, 2026, 7:16 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Interim Buprenorphine Treatment to Bridge Waitlist Delays: Stage II Evaluation

NCT03420313
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Buprenorphine/naloxone sublingual tablets
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 3, 2019 · Synced Oct 30, 2026, 7:16 PM EDT